This is Alzinova
Alzinova AB is a Swedish clinical-stage company specializing in the treatment of Alzheimer’s disease – one of the major health scourges, without effective treatment options. The Company’s proprietary AβCC peptide™ technology enables the development of disease-modifying therapies that with high precision could target the neurotoxic amyloid-β oligomers involved in the onset and progression of the disease.
Alzinova is a biopharmaceutical company dedicated to developing active and passive immunotherapies to treat Alzheimer's disease. Read more
Learn more about Alzinova's vision and long-term goal to help Alzheimer's patients live an active and independent life. Read more
Our goal is to develop a disease modifying therapeutic vaccine for the treatment of Alzheimer's disease. Read more
Board of Directors
Our Board of Directors is committed to strong corporate governance practices that promote and protect the long-term interests of our shareholders. Read more
Our management team combines in-depth industry experience and scientific expertise with strong commercial capacity. Read more